hrp0095p1-152 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

COVID-19 and precocious puberty: Does BMI play a role?

Pepino Carlotta , Fava Daniela , Pepe Alessia , Strati Marina , Paoloni Dalila , Patti Giuseppa , Elsa Maria Allegri Anna , Maghnie Mohamad , Di Iorgi Natascia

Background: Since COVID-19 the number of girls referred to pediatric endocrinologist for suspected precocious puberty (PP) and early puberty (EP) has increased. The aim of the study was to evaluate the incidence, the anthropometric, biochemical and radiological characteristics of PP during the COVID-19 pandemic, compared to previous years.Methods: We retrospectively evaluated medical records of 464 females (F) referred t...

hrp0097p1-520 | Growth and Syndromes | ESPE2023

Does cervical medullary decompression have an impact on growth in children with achondroplasia?

Fava Daniela , Tedesco Caterina , Angelelli Alessia , Napoli Flavia , Pepino Carlotta , Pepe Alessia , Teruzzi Daniela , Pisati Angelica , Fay Cortella Maria , Binelli Maria , Maghnie Mohamad , Di Iorgi Natascia , Elsa Maria Allegri Anna

Background: Foramen magnum stenosis (FMS) is a life-threatening complication in children with achondroplasia (ACH) which may require cervicomedullary decompression (CMD). There is no evidence if FMS and CMD affects growth in children with ACH.Aim: To evaluate the impact of FSM and CMD surgery on anthropometric measurements in children with ACH.Methods: Sixty-five patients with ACH ...

hrp0098fc7.4 | GH and IGFs | ESPE2024

Growth Hormone Response to Glucagon Stimulation Test in Transitional Age

Fava Daniela , Vanorio Barbara , Santucci Chiara , Parodi Stefano , Pepe Alessia , Repetto Agnese , Caridi Claudia , Acquarone Lucia , Data Erica , Merlo Silvia , Napoli Flavia , Tedesco Caterina , Angelelli Alessia , Panciroli Marta , Casalini Emilio , Di Iorgi Natascia , Maghnie Mohamad

Context: In the diagnosis of permanent GH deficiency (GHD) during the transition phase, the 2019 AACE guidelines recommended peak GH-cutoffs of ≤3µg/L and ≤1µg/L for the glucagon test (GST), while a recent investigation identified a value <5.8μg/L as a suitable gold standard (Fava et al, Journal of Clinical Endocrinology and Metabolism, 2024). However, the clinical applicability of this cutoff remains to be confirmed and the potential c...